Dr. Dominik Schaffner

And they need to be implemented as part of a greater framework of longevity medicine with medical oversight.

Okay, so these drugs are part of the GLP-1 family, which are glucagon-like peptides.

In saying so, they regulate your satiety, they regulate your insulin and your bowel movements and passage, essentially, right?

So what they do is they cause a delay in your stomach emptying.

And in saying so, you feel...

your satiety levels are higher for longer, right?

Now, semaglutide or Sempic is a GLP-1 medication that is primarily designed to be an anti-diabetic, but has also weight loss properties.

It works via one receptor.

GLP-2, like Giuseppatide or Mocharo or Vigovi, works via two receptors.

And Ritaltrutide, that everyone is talking about at the moment, works via three different receptor pathways.

Now, in saying so, Ritaltrutide is currently still in phase three clinical trials.

So it's not on the market and it's not available.

It's not available.

There's a patent application on Ritaltrutide at the moment, and it's still undergoing rigorous clinical trials.

Absolutely, Kyle.

This is a very important point you raised there.

So there's a whole category of peptides classified as research-only peptides.

These are the peptides that you can just order in a web store that is potentially run by someone who saw a niche in the market, not a medical expert.

So this is highly critical because these substances don't undergo any testing.

Best case scenario, you're just getting saline.